Pfizer, BioNTech ink deal with New Zealand for COVID-19 vaccine

Published On 2020-10-15 03:30 GMT   |   Update On 2020-10-15 03:31 GMT

Sydney: The New Zealand government signed a deal on Monday to buy 1.5 million COVID-19 vaccines from Pfizer Inc and Germany's BioNTech, with delivery potentially as early as the first quarter of 2021.The government did not disclose financial terms of the deal, its first vaccine purchase, which will provide enough doses to vaccinate 750,000 people. Officials said talks were continuing with...

Login or Register to read the full article

Sydney: The New Zealand government signed a deal on Monday to buy 1.5 million COVID-19 vaccines from Pfizer Inc and Germany's BioNTech, with delivery potentially as early as the first quarter of 2021.

The government did not disclose financial terms of the deal, its first vaccine purchase, which will provide enough doses to vaccinate 750,000 people. Officials said talks were continuing with other drug companies to secure more vaccine supplies for the country of 5 million people and further announcements were expected next month.

"The additional agreements will ensure that once the portfolio is completed, we will have sufficient COVID-19 vaccines for the whole population," Research Minister Megan Woods said in a statement.

The Pfizer-BioNTech vaccine is one of the leading candidates in the race to be the first to get regulatory approval in the United States and Europe.

Read also: India needs ramping up cold chain facilities for safe delivery of COVID vaccines, says Experts

New Zealand appeared to have stamped out community transmission of COVID-19 earlier this year following a tough nationwide lockdown. A renewed outbreak in the city of Auckland in August was also brought under control with fresh lockdown measures.

The country has reported just over 1,500 cases, including 25 deaths, far less than most other developed nations.

Read also: Also RPfizer modifies Covid vaccine study protocol to include adolescents



Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News